RBIS as a prognostic biomarker for progression-free survival in prostate cancer: insights from bioinformatics and immune infiltration analysis
RBIS represents a promising biomarker for PCa diagnosis, prognosis, and therapy. Further research is required to validate these findings and advance RBIS's clinical application, offering novel insights into PCa management.
Authors
- Yutong Fang
- Zexiao Chen
- Jianhua Zhang (ORCID: https://orcid.org/0000-0001-5412-9860)
Institutions
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1007/s12672-025-02083-4
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00